<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112525</url>
  </required_header>
  <id_info>
    <org_study_id>CCER 2016-01490</org_study_id>
    <nct_id>NCT03112525</nct_id>
  </id_info>
  <brief_title>DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic</brief_title>
  <acronym>DAPHNE</acronym>
  <official_title>DAPHNE Study: Real-Life Observational Study to Evaluate the Impact of the CYP3A4/5/7 and P-gp Pharmacogenetics and Phenotypic Activity on the Pharmacokinetic Profile of the Direct Oral Anticoagulants Rivaroxaban and Apixaban in Hospitalised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New/direct oral anticoagulants (NOAC/DOAC), like apixaban and rivaroxaban, are an interesting&#xD;
      alternative to unfractionated or low molecular weight heparin relayed by oral anti-vitamin K&#xD;
      anticoagulants (VKA) for the treatment of venous thromboembolism and atrial fibrillation.&#xD;
      This new generation of anticoagulants directly inhibit a factor in the blood coagulation&#xD;
      pathway and have a wide therapeutic range overcoming several practical issues associated with&#xD;
      VKA therapy including the need of routine coagulation monitoring potentially simplifying&#xD;
      patient management. However, despite this wide therapeutic range, a large interindividual&#xD;
      dose variability related to factors such as age, body surface, smoking, concomitant diseases&#xD;
      as well as differences in drug metabolism, could put susceptible patients at risk for&#xD;
      uncontrolled bleeding. Both rivaroxaban and apixaban are cleared primarily via cytochrome&#xD;
      P450 (CYP) mediated hepatic metabolism, mainly CYP3A, and renal excretion, involving the&#xD;
      P-glycoprotein (P-gp). Both CYP3A and P-gp activity show important interindividual variations&#xD;
      due to drug interactions and/or genetic polymorphisms in corresponding genes.&#xD;
&#xD;
      The aim of the current study is to evaluate the impact of cytochrome activity and relevant&#xD;
      polymorphisms on rivaroxaban/apixaban dosage regimen or treatment efficacy in a hospital&#xD;
      setting. The safety issue in this context is particularly relevant, since hospitalisation is&#xD;
      linked to a modification of the patient's treatment with often an increase in the number of&#xD;
      medications. The resulting changes in metabolism due to modified cytochrome and transporter&#xD;
      activities could affect rivaroxaban/apixaban blood concentrations. Our central hypothesis is&#xD;
      that genotype and/or phenotype in CYP3A4/5/7 or P-gp may influence the rivaroxaban/apixaban&#xD;
      plasma concentration and increase the risk of thrombotic or hemorrhagic events. Thus,&#xD;
      investigating how the patient's genotype and/or phenotype for CYP3A4/5/7 and P-gp could&#xD;
      potentially alter the bio-disponibility of rivaroxaban and apixaban and therefore the risk to&#xD;
      develop adverse events or inefficacy would be of particular interest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">January 7, 2021</completion_date>
  <primary_completion_date type="Actual">January 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison Apixaban Area Under the Curve (AUC) according to patient CYP3A phenotype</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Rivaroxaban AUC according to patient P-gp phenotype</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Apixaban AUC according to patient CYP3A genotype</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Rivaroxaban AUC according to patient P-gp genotype</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison Apixaban AUC according to patient hepatic function</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Rivaroxaban AUC according to patient hepatic function</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Apixaban AUC according to patient renal function</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Rivaroxaban AUC according to patient renal function</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison adverse event (bleeding) occurrence according to patient CYP3A phenotype</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison adverse event (bleeding) occurrence according to patient P-gp phenotype</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison bleeding management outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Recording of all interventions, procedures and outcomes related to any reported bleeding</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Anticoagulants and Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>Patient under Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient under Apixaban</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CYP3A4/5 and P-gp phenotyping</intervention_name>
    <description>Phenotyping using a simplified version of the Geneva cocktail</description>
    <arm_group_label>Patient under Apixaban</arm_group_label>
    <arm_group_label>Patient under Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>CYP3A4/5 and P-gp genotyping</intervention_name>
    <description>Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination</description>
    <arm_group_label>Patient under Apixaban</arm_group_label>
    <arm_group_label>Patient under Rivaroxaban</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atrial fibrillation, pulmonary embolism or deep-vein thrombosis, treated or&#xD;
        on long-term prophylaxis with rivaroxaban or apixaban in a real-life clinical setting. All&#xD;
        patients will be recruited at the Geneva University Hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understanding of French or English language and provide signed and dated informed&#xD;
             consent form.&#xD;
&#xD;
          -  Willing to comply with all study procedures and be available for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Male or female, aged 18 years or above.&#xD;
&#xD;
          -  Diagnosed with atrial fibrillation, deep-vein thrombosis or pulmonary embolism and&#xD;
             under rivaroxaban or apixaban drug treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical study that may interfere with participation in this study.&#xD;
&#xD;
          -  Under rivaroxaban or apixaban for prophylaxis of deep-vein thrombosis and pulmonary&#xD;
             embolism in patients undergoing knee or hip replacement surgery.&#xD;
&#xD;
          -  Anything that would place the individual at increased risk or preclude the&#xD;
             individual's full compliance with or completion of the study.&#xD;
&#xD;
          -  Known allergy to midazolam or to fexofenadine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jules Desmeules, Pr.</last_name>
    <role>Study Director</role>
    <affiliation>HUG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria Rollason</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HUG</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Victoria Rollason</investigator_full_name>
    <investigator_title>Pharmacologist</investigator_title>
  </responsible_party>
  <keyword>rivaroxaban</keyword>
  <keyword>apixaban</keyword>
  <keyword>cytochrome</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>transporter</keyword>
  <keyword>polymorphism</keyword>
  <keyword>genotyping</keyword>
  <keyword>phenotyping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

